The multiple sclerosis risk gene IL22RA2 contributes to a more severe murine autoimmune neuroinflammation

Genes and Immunity

Volumn 15, Issue 7, 2014, Pages 457-465

  Laaksonen, H ^a   Guerreiro Cacais, A O ^a   Adzemovic, M Z ^a   Parsa, R ^a   Zeitelhofer, M ^a   Jagodic, M ^a   Olsson, T ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 22; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; INTERLEUKIN RECEPTOR; INTERLEUKIN-22 RECEPTOR; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CELL INFILTRATION; CONTROLLED STUDY; DEMYELINATION; DISEASE COURSE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENE; GENE IL22RA2; IMMUNOCOMPETENT CELL; KNOCKOUT MOUSE; LYMPHOID TISSUE; MOUSE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; WILD TYPE; ANIMAL; CENTRAL NERVOUS SYSTEM; GENETICS; IMMUNOLOGY; METABOLISM; MYELIN SHEATH; PATHOLOGY;

ANIMALS; CENTRAL NERVOUS SYSTEM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; LYMPHOID TISSUE; MICE; MULTIPLE SCLEROSIS; MYELIN SHEATH; RECEPTORS, INTERLEUKIN; RNA, MESSENGER;

EID: 84908255878     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2014.36     Document Type: Article

References (29)

1. Sobocki P, Pugliatti M, Lauer K, Kobelt G. Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult Scler 2007; 13: 1054-1064.
2. Sawcer S, Hellenthal G, Pirinen M, Spencer CCA, Patsopoulos NA, Moutsianas L et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214-219.
3. Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013; 45: 1353-1360.
4. Gregory AP, Dendrou CA, Attfield KE, Haghikia A, Xifara DK, Butter F et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 2012; 488: 508-511.
5. Couturier N, Bucciarelli F, Nurtdinov RN, Debouverie M, Lebrun-Frenay C, Defer G et al. Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain 2011; 134: 693-703.
6. Lundström W, Highfill S, Walsh STR, Beq S, Morse E, Kockum I et al. Soluble IL7Ra potentiates IL-7 bioactivity and promotes autoimmunity. Proc Natl Acad Sci USA 2013; 110: E1761-E1770.
7. Beyeen AD, Adzemovic MZ, Ockinger J, Stridh P, Becanovic K, Laaksonen H et al. IL-22RA2 associates with multiple sclerosis and macrophage effector mechanisms in experimental neuroinflammation. J Immunol 2010; 185: 6883-6890.
8. Silverberg MS, Cho JH, Rioux JD, McGovern DPB, Wu J, Annese V et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet 2009; 41: 216-220.
9. Strange A, Capon F, Spencer CCA, Knight J, Weale ME, Allen MH et al. A genomewide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010; 42: 985-990.
10. Trynka G, Hunt KA, Bockett NA, Romanos J, Mistry V, Szperl A et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet 2011; 43: 1193-1201.
11. Xu W, Presnell SR, Parrish-Novak J, Kindsvogel W, Jaspers S, Chen Z et al. A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc Natl Acad Sci USA 2001; 98: 9511-9516.
12. Dumoutier L, Lejeune D, Colau D, Renauld JC. Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J Immunol 2001; 166: 7090-7095.
13. Jones BC, Logsdon NJ, Walter MR. Structure of IL-22 bound to its high-affinity IL-22R1 chain. Structure 2008; 16: 1333-1344.
14. Huber S, Gagliani N, Zenewicz LA, Huber FJ, Bosurgi L, Hu B et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012; 491: 259-263.
15. Martin JCJ, Bériou G, Heslan M, Chauvin C, Utriainen L, Aumeunier A et al. Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acid. Mucosal Immunol 2014; 7: 101-113.
16. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity 2004; 21: 241-254.
17. Sonnenberg GF, Fouser LA, Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 2011; 12: 383-390.
18. Liang SC, Tan X-Y, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203: 2271-2279.
19. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-240.
20. Kreymborg K, Etzensperger R, Dumoutier L, Haak S, Rebollo A, Buch T et al. IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol 2007; 179: 8098-8104.
21. Mildner A, Mack M, Schmidt H, Brück W, Djukic M, Zabel MD et al. CCR2\+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain 2009; 132: 2487-2500.
22. King IL, Dickendesher TL, Segal BM. Circulating Ly-6C\+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 2009; 113: 3190-3197.
23. vanOosten B, Barkhof F, Truyen L, Boringa J, Bertelsmann F, vonBlomberg B et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47: 1531-1534.
24. Arnason B, Jacobs G, Hanlon M, Clay B, Noronha A, Auty A et al. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53: 457-465.
25. Wolk K, Witte E, Hoffmann U, Doecke W, Endesfelder S, Asadullah K et al. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease. J Immunol 2007; 178: 5973-5981.
26. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007; 13: 1173-1175.
27. Ke Y, Sun D, Jiang G, Kaplan HJ, Shao H. IL-22-induced regulatory CD11b\+ APCs suppress experimental autoimmune uveitis. J Immunol 2011; 187: 2130-2139.
28. Storch MK, Stefferl A, Brehm U, Weissert R, Wallström E, Kerschensteiner M et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998; 8: 681-694.
29. Adzemovic MZ, Zeitelhofer M, Eriksson U, Olsson T, Nilsson I. Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood-brain barrier integrity and by modulating the peripheral immune response. PLoS ONE 2013; 8: e56586.